Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Quest Diagnostics

The diagnostic testing company is scheduled to report first-quarter earnings on April 18. Analysts, on average, anticipate earnings of $1.01 a share on revenue of $1.88 billion.

"All in, we view DGX as able to meet current growth expectations this year, although Medicare hits should be more daunting in 2013," Bank of America Merrill Lynch analysts wrote in a March 12 report. "By then, we hope to see a rebound in utilization, as well as the impact of cost cutting."

Forward Annual Dividend Yield: 1.1%

Rated "A- (Buy)" by TheStreet Ratings: The company's fourth-quarter gross profit margin was about the same as it was the previous year.

Quest Diagnostics has weak liquidity. Its Quick Ratio is 0.69, which demonstrates a lack of ability to meet its short-term cash needs.

In the fourth quarter, stockholders' net worth decreased 8.44% from the prior year.

TheStreet Ratings' price target is $69.24.


PNM Resources

The energy company reported last month fourth-quarter earnings of $176.4 million, or $1.96 a share, a swing from a year-earlier loss of $45.2 million, or 49 cents a share.

"Q4 results beat our expectations and represent a strong ending to a very good 2011," Wells Fargo analysts wrote in a March 1 report. "In addition, a 16% dividend hike announcement is a nice start to 2012. PNM affirmed its 2012 EPS guidance and its long-term goal to provide total return in the top quartile of the industry. We are reiterating our 2012-14 estimates and our Market Perform rating. While we think PNM has a good chance to achieve its long-term top-quartile return target, numerous near-term regulatory uncertainties keep us from getting more aggressive with our rating."

Forward Annual Dividend Yield: 3.1%

Rated "B (Buy)" by TheStreet Ratings: The company's fourth-quarter gross profit margin has increased from the previous year.

PNM Resources has very weak liquidity. Its Quick Ratio is 0.47, which demonstrates a lack of ability to meet its short-term cash needs.

In the fourth quarter, stockholders' net worth decreased 3.80% from the prior year.

TheStreet Ratings' price target is $23.91.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

If you liked this article you might like

What a Difference a Day Makes for New SEC Rule

Jim Cramer: Agilent Technology Has Been One of My Favorites

Jim Cramer -- Agilent Is 'Continuing to Defy Gravity'

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis